Clinical Trial Supply Market- Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Clinical Trial Supply Market is segmented by Clinical Phase (Phase 1, Phase 2, Phase 3, and others), Services (Manufacturing, Storage and Distribution, and Supply Chain Management), Application (Oncology, Central Nervous System, Infectious Diseases, Metabolic Disorder, Cardiovascular and Others), End-User (Pharmaceuticals, Biologics, Medical Devices, and Others), Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Clinical Trial Supply Market Size
Study Period: 2022-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 6.5 %
Clinical Trial Supply Market Size

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The clinical trial supply market is expected to register a CAGR of 6.5% over the forecast period, 2022-2027.

COVID-19 has affected almost every sector and so had a substantial effect on clinical research activities across the globe. The lockdown imposed by the government has created challenges and obstacles for clinical research studies as many clinical research organizations were not able to initiate new trials, which led to difficulties in recruiting new subjects and experiencing lower follow-up rates in the ongoing clinical trials. However, over a few months, the trials which had been pushed aside due to COVID-19 had gained significant traction. For instance, in the journal Clinical Pharmacology and Therapeutics 2022 an article titled, “The impact of COVID-19 in the initiation of clinical trials in Europe and the United States” summarizes that the United States reported a 3% increase in overall clinical trials studies while European countries showed the overall increase of 10% in clinical trials studies. Although COVID-19 has affected the non-COVID-19 clinical trials in the United States and Europe, the emergence of COVID-19 led to the development of many new vaccines launched by various companies, which directly increased the overall number of clinical trials in the year 2020 as compared to 2019.

Increasing R&D expenditure of pharmaceutical and biopharmaceutical companies, increasing number of registered clinical trials, and increasing decentralization of clinical trials are some of the key factors driving the market growth. The spending on the R&D market and the introduction of new drugs have increased in the past two decades. For instance, an article published in Congressional Budget Office, 2021 reports that in the year 2019, the pharmaceutical industry spent 83 billion dollars on R&D, this amount was 10 times what the industry used to spend in the 1980s. Additionally, the number of new drug approval increased up to 60% between 2010 to 2020, with a peak of 50 novel approval of drugs by the Food and Drug Administration (FDA) in 2021.

The increasing number of registered clinical trials had a direct impact on driving the clinical trial supply market. For instance, as per the data reported on the clinicaltrials.gov site, in June 2022, the total number of clinical trial studies globally reported was 419,487 while 2,119 were registered clinical trials in 2000. The increase in expenditure in the R&D market has boosted the novel drug development process, which has boosted the number of clinical trials, thereby driving the clinical trials supply market.

Due to the high cost of the drug development market and research for some rare diseases are very challenging and requires a specific group of people to conduct a clinical trial, the chances for the failure of clinical trials for such studies are quite high, which may slow down the growth of this market.

Scope of the Report

As per the scope of this report, clinical trial supply is defined as the supply of materials required for conducting a clinical trial and this includes 24-hour collection and delivery of biological, etc. The Clinical Trial Supply Market is segmented by Clinical Phase (Phase 1, Phase 2, Phase 3, and Others), Services (Manufacturing, Storage and Distribution, and Supply Chain Management), Application (Oncology, Central Nervous System, Infectious Diseases, Metabolic Disorder, Cardiovascular and Others), End-User (Pharmaceuticals, Biologics, Medical Devices, and Others), Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

Report scope can be customized per your requirements. Click here.

Key Market Trends

Biologics Segment is Expected to Witness Significant Growth Over the Forecast Period

Biologics and biosimilars are made from living cells through highly complex manufacturing processes and are expected to witness steady growth, owing to increasing research activities such as the development of biosimilar products, and nanoparticle-based drug delivery systems in the field of genetics and biotechnology. In recent years the use of biologics such as hormones, blood products, vaccines, genes, insulin, and monoclonal antibody (mAb) products are used as the most advanced therapies for the treatment of diseases like Crohn’s disease, rheumatoid arthritis, and other autoimmune diseases. The increased widespread use has witnessed significant growth of biologics over the forecast period.

With the rapid increase in the number of cancer cases and increased approaches of researchers for the use of biologics for cancer treatment are driving its market. According to the data by the Centers for Disease Control and Prevention published, the incidence of cancer is expected ti increase by nearly 50%, from 1,534,500 in 2015 to 2,286,300 in 2050. The use of biologics therapy over traditional cancer treatment therapy is increasing as biologic therapies use the body's immune systems and abilities to fight cancer or heal healthy tissue after treatment. For instance, the Journal of Global Oncology 2020, reported that biologics accounted for an overall 55% of the total expenditure on antineoplastic drugs in the health care system. Thus, a higher incidence of cancer cases is driving the growth of biologics, and biologics are expected to witness significant growth due to aforesaid reasons.

Clinical Trial Supply Market Trends

North America had the largest regional market for clinical trial supplies till 2027

The reason North America had the largest clinical trial supply market worldwide is due to the rising number of clinical trials worldwide. The increasing technological advancements, government funding, and increasing incidence of diseases resulted to drive the clinical trial supply market in North America. Major CROs and biopharmaceutical companies have their hub in this region because of a higher number of large-scale pharma R&D clinical trials conducted in these regions. Also, North America is the largest clinical trial supply market and the most effective regulation of clinical trials with advanced therapy such as electronic records and signatures, protection of human subjects, and good clinical practices for non-clinical laboratory studies eases the overall clinical trial studies.

North America accounts for the largest number of projects in the Phase 2 trial in 2020 and this trend led to high investments in R&D by industry and other out-of-industry sponsors. For instance, in clinical trials logistic survey in 2021, states that about 60% of clinical trials in phase 2 are outsourced. Due to the high concentration of pharmaceutical leaders, innovative combinations of approved and novel treatments have driven the number of phase 2 trial studies. The high prevalence of cancer in the United States led to the high investment in R&D is another driving feature of the clinical trial supply market in North America. For instance, Cancer.Org Cancer Facts and Figure accounted for 609,360 new cancer cases in 2022 which was 0.12 % higher than reported in 2021. Thus, a increasing incidence of cancer cases reported ever year in North America is driving the clinical trial supply market in that region.

Thus, for the reason mentioned above the clinical trial supply market in North America has the largest market and is expected to show significant growth over the forecast period.

Clinical Trial Supply Market Forecast

Competitive Landscape

The Clinical Trial Supply market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares key players in the clinical trial supplies market include Thermo Fisher Scientific (US), Catalent, Inc. (the US), Parexel (US), Almac Group (UK), Marken (US), Piramal Pharma Solutions (India), UDG Healthcare (Ireland).

Recent Development

· In April 2022 PPD (Pharmaceutical Product Development) clinical research business of Thermo Fisher Scientific Inc., and Matrix Clinical Trials, a Matrix Medical Network offering, have collaborated to bring clinical trials to patients with an innovative decentralized clinical trial (DCT) solution.

· In April 2021, Parexel collaborated with Veeva Systems to improve their clinical processes for clinical trial delivery and enhance Veeva’s cloud technology

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing R&D expenditure of pharmaceutical and biopharmaceutical companies

      2. 4.2.2 Increasing number of registered clinical trials

      3. 4.2.3 Increasing decentralization of clinical trials

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Drug Development

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 Clinical Phase Type

      1. 5.1.1 Phase 1

      2. 5.1.2 Phase 2

      3. 5.1.3 Phase 3

      4. 5.1.4 Others

    2. 5.2 Product Type

      1. 5.2.1 Manufacturing

      2. 5.2.2 Storage and Distribution- Cold Chain Based/Non-Cold Chain Based

      3. 5.2.3 Supply Chain Management

    3. 5.3 End-Users

      1. 5.3.1 Pharmaceuticals

      2. 5.3.2 Biologics

      3. 5.3.3 Medical Devices

      4. 5.3.4 Others

    4. 5.4 Application

      1. 5.4.1 Oncology

      2. 5.4.2 CNS

      3. 5.4.3 Infectious Disease

      4. 5.4.4 Metabolic Disorder

      5. 5.4.5 Cardiovascular

      6. 5.4.6 Others

    5. 5.5 Geography

      1. 5.5.1 North America

        1. 5.5.1.1 United States

        2. 5.5.1.2 Canada

        3. 5.5.1.3 Mexico

      2. 5.5.2 Europe

        1. 5.5.2.1 Germany

        2. 5.5.2.2 United Kingdom

        3. 5.5.2.3 France

        4. 5.5.2.4 Italy

        5. 5.5.2.5 Spain

        6. 5.5.2.6 Rest of Europe

      3. 5.5.3 Asia-Pacific

        1. 5.5.3.1 China

        2. 5.5.3.2 Japan

        3. 5.5.3.3 India

        4. 5.5.3.4 Australia

        5. 5.5.3.5 South Korea

        6. 5.5.3.6 Rest of Asia-Pacific

      4. 5.5.4 Middle East and Africa

        1. 5.5.4.1 GCC

        2. 5.5.4.2 South Africa

        3. 5.5.4.3 Rest of Middle East and Africa

      5. 5.5.5 South America

        1. 5.5.5.1 Brazil

        2. 5.5.5.2 Argentina

        3. 5.5.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Thermo Fisher Scientific (US),

      2. 6.1.2 Catalent, Inc. (US)

      3. 6.1.3 Parexel (US)

      4. 6.1.4 Almac Group (UK)

      5. 6.1.5 Marken (US)

      6. 6.1.6 Piramal Pharma Solutions (India)

      7. 6.1.7 UDG Healthcare (Ireland).

      8. 6.1.8 Recipharm (Sweden)

      9. 6.1.9 Myonex (India)

      10. 6.1.10 Rubicon (India)

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Clinical Trial Supply Market market is studied from 2022 - 2027.

The Global Clinical Trial Supply Market is growing at a CAGR of 6.5% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Thermo Fisher Scientific, Catalent, Paraxel, Almac Group, Marken are the major companies operating in Global Clinical Trial Supply Market .

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!